Efficacy and safety of Xingnaojing Injection in treatment of post-stroke disorders of consciousness： A systematic review and meta-analysis
10.19845/j.cnki.zfysjjbzz.2025.0150
- VernacularTitle:醒脑静注射液在脑卒中后意识障碍治疗中的疗效和安全性：系统评价和Meta分析
- Author:
Liangsheng CHEN
1
;
Yun LUO
2
Author Information
1. 赣南医科大学， 江西 赣州 341000；赣南医科大学第一附属医院康复医学科， 江西 赣州 341000
2. 赣南医科大学第一附属医院康复医学科， 江西 赣州 341000
- Publication Type:Journal Article
- Keywords:
Stroke;
Xingnaojing Injection;
Disorders of consciousness;
Consciousness function;
Meta-analysis
- MeSH:
Stroke
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(9):796-806
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the efficacy and safety of Xingnaojing Injection （XNJ） in the treatment of post-stroke disorders of consciousness （PSDOC）. Methods PubMed， Embase， the Cochrane Library， Web of Science， VIP， CNKI， Wanfang Data， and SinoMed were searched for related randomized controlled trials （RCT） published up to July 2025. RevMan 5.4 and Stata 16.0 were used for data extraction and analysis. Results A total of 48 RCT were included， with 4 570 patients in total. The RCT included had relatively low overall risk of bias. The meta-analysis showed that compared with conventional treatment alone， XNJ combined with conventional treatment significantly improved the Glasgow Coma Scale （GCS） score of patients with PSDOC （mean difference=2.62， 95% confidence interval： 2.37-2.86， I²=66%， P0.000 01）. The subgroup analyses showed that XNJ administered at three dosages （20 ml， 30 ml， 40 ml） and for different treatment durations （1 week， 2 weeks， 4 weeks） could effectively improve the GCS score of patients， and it also showed efficacy in patients with hemorrhagic/ischemic stroke and disorders of consciousness. Nine RCT reported the adverse reactions including nausea， rash， and mild dizziness during the trial， which were resolved after the infusion rate was slowed down. Conclusion XNJ is a safe and effective therapy for improving consciousness in patients with PSDOC.
